A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices / Medical Express
medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Saturday, March 14, 2026, 11:21 pm / permalink 20776 / 4 stories in 45 hrs
Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision / MedCity
Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #healthcarefinance
Saturday, March 14, 2026, 8:21 pm / permalink 20771 / 2 stories in 2 days
Roche’s big hope breast cancer drug fails in crucial first-line trial / Endpoints
Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Saturday, March 14, 2026, 7:21 pm / permalink 20770 / 5 stories in 2 days
Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia / OncoDaily
oncodaily - Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared a post by NEJM, […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Saturday, March 14, 2026, 12:23 pm / permalink 20760 / 2 stories in 2 days
Grail names new CEO as Bob Ragusa retires / Endpoints
Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...
#healthcare #biotech #medicaldevices #oncology #healthcarefinance #cancerresearch
Saturday, March 14, 2026, 4:21 am / permalink 20744 / 5 stories in 2 days
Ipsen pulls cancer drug Tazverik from market over safety risks / Endpoints
Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda #productrecall #oncology #cancerresearch
Saturday, March 14, 2026, 12:23 am / permalink 20738 / 3 stories in 2 days